- Investing Ideas
- U.S. Pharmaceuticals & Biotech Sustainable Track Record
U.S. Pharmaceuticals & Biotech Sustainable Track Record
Results
12
Companies which have reinvested earnings to sustain 10% yearly growth over 5 years.
12 companies
CorMedix
Market Cap: US$685.7m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$8.75
7D
11.5%
1Y
-24.7%
Protalix BioTherapeutics
Market Cap: US$186.9m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$2.32
7D
0.9%
1Y
50.6%
Aurinia Pharmaceuticals
Market Cap: US$2.0b
A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
AUPH
US$15.61
7D
-9.4%
1Y
105.7%
Rigel Pharmaceuticals
Market Cap: US$716.4m
A biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
RIGL
US$38.72
7D
0.08%
1Y
104.5%
Exelixis
Market Cap: US$14.0b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$55.85
7D
2.0%
1Y
21.0%
Medpace Holdings
Market Cap: US$15.9b
Provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
MEDP
US$557.60
7D
5.8%
1Y
73.4%
TG Therapeutics
Market Cap: US$7.6b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$53.31
7D
-4.5%
1Y
45.2%
ACADIA Pharmaceuticals
Market Cap: US$4.4b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$25.97
7D
2.6%
1Y
24.0%
Catalyst Pharmaceuticals
Market Cap: US$3.9b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$31.45
7D
-0.2%
1Y
46.6%
Eli Lilly
Market Cap: US$1.1t
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
LLY
US$1,213.91
7D
0.5%
1Y
55.5%
Earth Science Tech
Market Cap: US$38.9m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.14
7D
-15.6%
1Y
-30.8%
CapForce
Market Cap: US$204.3m
A precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally.
CFOR
US$16.50
7D
83.3%
1Y
248.8%